CORE
CO
nnecting
RE
positories
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Research partnership
About
About
About us
Our mission
Team
Blog
FAQs
Contact us
Community governance
Governance
Advisory Board
Board of supporters
Research network
Innovations
Our research
Labs
Best supportive care in clinical trials: Review of the inconsistency in control arm design
Authors
AP Abernethy
NI Cherny
+4 more
DC Currow
RD Nipp
F Strasser
SY Zafar
Publication date
1 January 2015
Publisher
'Springer Science and Business Media LLC'
Doi
Cite
View
on
PubMed
Abstract
© 2015 Cancer Research UK. All rights reserved. Best supportive care (BSC) as a control arm in clinical trials is poorly defined. We conducted a review to evaluate clinical trials' concordance with published, consensus-based framework for BSC delivery in trials.Methods:A consensus-based Delphi panel previously identified four key domains of BSC delivery in trials: multidisciplinary care; supportive care documentation; symptom assessment; and symptom management. We reviewed trials including BSC control arms from 2002 to 2014 to assess concordance to BSC standards and to selected items from the CONSORT 2010 guidelines.Results:Of 408 articles retrieved, we retained 18 after applying exclusion criteria. Overall, trials conformed to the CONSORT guidelines better than the BSC standards (28% vs 16%). One-third of articles offered a detailed description of BSC, 61% reported regular symptom assessment, and 44% reported using validated symptom assessment measures. One-third reported symptom assessment at identical intervals in both arms. None documented evidence-based symptom management. No studies reported educating patients about symptom management or goals of therapy. No studies reported offering access to palliative care specialists.Conclusions:Reporting of BSC in trials is incomplete, resulting in uncertain internal and external validity. Such studies risk systematically over-estimating the net clinical effect of the comparator arms
Similar works
Full text
Available Versions
OPUS - University of Technology Sydney
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:opus.lib.uts.edu.au:10453/...
Last time updated on 18/10/2019
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
info:doi/10.1038%2Fbjc.2015.19...
Last time updated on 04/12/2019